Výsledky vyhledávání - "Isao Tsumiyama"

Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan

Autor: Kumiko, Hosono, Kazuko, Matsumoto, Miki, Shimbo, Isao, Tsumiyama, Chihiro, Kato

Publikováno v: Modern Rheumatology. 33:381-391

Objectives To assess the real-world safety and effectiveness of canakinumab in patients in Japan with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate kinase deficiency/hyperimmunoglobulinaemia D with periodic fever

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd3bae415581beb8ba48247954955f1
https://doi.org/10.1093/mr/roac041

Zobrazit plný text záznamu

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Autor: Krishnan Ramanathan, Jin Nakahara, Takahiko Saida, Martin Merschhemke, Wendy Su, Takayoshi Kurosawa, Dieter A. Häring, Roman Willi, Ratnakar Pingili, Bernd C. Kieseier, Denis V Sazonov, Martin Zalesak, Jun-ichi Kira, Isao Tsumiyama

Publikováno v: Multiple Sclerosis Journal. 28:1229-1238

Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. Objective: To investigate the efficacy and safety of ofatumu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ab5ed4bc3e3d83790fe94e2f98263f
https://doi.org/10.1177/13524585211055934

Zobrazit plný text záznamu

Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity

Autor: Deborah L. Keefe, Isao Tsumiyama, Misako Sano, Koutaro Yokote

Publikováno v: Diabetes, Obesity and Metabolism. 22:1102-1110

Aims LIK066 (licogliflozin) is a dual sodium glucose co-transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. Materials and metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5429fc89d8104d3c6954c720aaf9738
https://doi.org/10.1111/dom.14006

Zobrazit plný text záznamu

Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

Autor: Hiroki Murayama, Naotsugu Oyama, Yohei Shinfuku, Tomoko Hayashi, Isao Tsumiyama, Tomoko Taniguchi

Publikováno v: Expert opinion on pharmacotherapy. 21(1)

Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with >750...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b994cb95a429e7d96afb97eb30171c
https://pubmed.ncbi.nlm.nih.gov/31689132

Zobrazit plný text záznamu

Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients

Autor: Hiroki Murayama, Mitsutoshi Toda, Isao Tsumiyama, Naotsugu Oyama, Tomoko Taniguchi, Yohei Shinfuku, Yoshio Tanaka

Background: Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown. Research design and methods: This 2-year post-mar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d18276745a2620703bdc4b16cf4eda1

Zobrazit plný text záznamu

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study

Autor: Manabu Suzuki, Takahisa Hirose, Isao Tsumiyama

Publikováno v: Diabetes Therapy

Introduction To assess the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM), inadequately controlled on stable long-acting, intermediate-acting, or pre-mixed insulin, with or without conc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec03d75c061bb5bbcc329c412738c5be
https://doi.org/10.1007/s13300-015-0147-6

Zobrazit plný text záznamu

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

Autor: Kazuo Nagato, Yasuto Itoyama, Philipp von Rosenstiel, Takayoshi Kurosawa, Takahiko Saida, Seiji Kikuchi, Lixin Zhang-Auberson, Jun Ichi Kira, Isao Tsumiyama, Qi Hao

Publikováno v: BMC Neurology

Background A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114149d2d7f67351799e46b41d03064e

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání